Horizon Therapeutics (HZNP) Tepezza Shortage 'Seems Manageable' - BMO
Tweet Send to a Friend
BMO Capital analyst Gary Nachman reiterated an Outperform rating and $110.00 price target on Horizon Therapeutics (NASDAQ: HZNP), saying while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
